Related Experiment Video

Updated: Jun 7, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Platelet Aggregation, Thromboxane A(2), Prostacyclin Generation and Platelet Sensitivity to Prostacyclin during the

M Viigimaa1, T Jôudu, U Keis

  • 1Department of Cardiology, University Hospital, Puusepa Str. 8, EE 2400, Tartu, Estonia.

Platelets
|November 4, 2010
PubMed

Insights

Platelet aggregation increases after myocardial infarction (MI), necessitating platelet inhibitor therapy. This study tracked platelet function and related substances during the first month post-MI.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Biochemistry

Background:

  • Myocardial infarction (MI) triggers significant cardiovascular and hematological changes.
  • Understanding early post-MI platelet behavior is crucial for therapeutic interventions.

Purpose of the Study:

  • To investigate changes in platelet aggregation, thromboxane A, prostacyclin, and platelet sensitivity to prostacyclin in the first month after MI.
  • To assess the need for antiplatelet therapy in acute MI patients.

Main Methods:

  • Simultaneous measurement of platelet aggregation, plasma thromboxane B (breakdown product of thromboxane A), and prostacyclin levels.
  • Evaluation of platelet sensitivity to prostacyclin at various time points post-MI.

Main Results:

  • Platelet aggregation was low on admission, peaking by day 7 and remaining elevated for four weeks.
  • Increased thromboxane B and prostacyclin levels were observed, peaking on day 3 post-MI.
  • Patients exhibited transient platelet resistance to prostacyclin, normalizing by week 4.

Conclusions:

  • Early post-MI phase is characterized by heightened platelet activity and altered responses to prostacyclin.
  • Results support the use of platelet inhibitors in managing patients following myocardial infarction.

More Related Videos

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Vascular Spasm01:16

Vascular Spasm

The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...